Scholar Rock Holding (SRRK) Net Income towards Common Stockholders (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Net Income towards Common Stockholders came in at -$101.4 million in Q1 2026, down 35.42% year-on-year from -$157.1 million in Q1 2025, and down 13.37% quarter-over-quarter from -$89.5 million in Q4 2025.
Scholar Rock Holding (SRRK) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$101.4 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 35.42% year-over-year to -$101.4 million in Q1 2026; TTM through Mar 2026 was -$715.2 million, a 166.34% decrease from a year earlier, with the FY2025 full-year figure at -$377.7 million, down 53.37% from the prior year.
- Net Income towards Common Stockholders declined to -$101.4 million in Q1 2026 per SRRK's latest filing, from -$89.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$9.2 million in Q1 2022 and bottomed at -$263.8 million in Q2 2025.
- The 5-year median for Net Income towards Common Stockholders is -$56.8 million (2024), against an average of -$80.2 million.
- Across the five-year window, Net Income towards Common Stockholders soared 93.69% in 2022 and sank 383.1% in 2023, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$41.8 million in 2022, then fell by 18.96% to -$49.7 million in 2023, then plunged by 36.16% to -$67.7 million in 2024, then sank by 32.26% to -$89.5 million in 2025, then declined by 13.37% to -$101.4 million in 2026.
- Per Business Quant, the three latest SRRK Net Income towards Common Stockholders figures stand at -$101.4 million (Q1 2026), -$89.5 million (Q4 2025), and -$260.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Scholar Rock Holding | 6.32 Bn | 6.32 Bn | - | -101.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101.45 Mn |
| Dec 31, 2025 | -89.48 Mn |
| Sep 30, 2025 | -260.46 Mn |
| Jun 30, 2025 | -263.83 Mn |
| Mar 31, 2025 | -74.91 Mn |
| Dec 31, 2024 | -67.66 Mn |
| Sep 30, 2024 | -65.66 Mn |
| Jun 30, 2024 | -60.31 Mn |
| Mar 31, 2024 | -56.83 Mn |
| Dec 31, 2023 | -49.69 Mn |
| Sep 30, 2023 | -46.00 Mn |
| Jun 30, 2023 | -42.09 Mn |
| Mar 31, 2023 | -44.43 Mn |
| Dec 31, 2022 | -41.77 Mn |
| Sep 30, 2022 | -46.45 Mn |
| Jun 30, 2022 | -43.90 Mn |
| Mar 31, 2022 | -9.20 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -87.69 Mn |
| Jun 30, 2021 | -77.06 Mn |